Alan Ezekowitz Buys 41,355 Shares of Septerna, Inc. (NASDAQ:SEPN) Stock

Septerna, Inc. (NASDAQ:SEPN) Director Alan Ezekowitz purchased 41,355 shares of the firm’s stock in a transaction on Thursday, March 6th. The stock was bought at an average cost of $6.00 per share, with a total value of $248,130.00. Following the completion of the acquisition, the director now directly owns 104,101 shares of the company’s stock, valued at $624,606. This trade represents a 65.91 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Alan Ezekowitz also recently made the following trade(s):

• On Tuesday, March 4th, Alan Ezekowitz purchased 7,491 shares of Septerna stock. The stock was bought at an average cost of $6.35 per share, with a total value of $47,567.85.

Septerna Price Performance

Shares of SEPN stock opened at $6.43 on Friday. The stock’s 50 day simple moving average is $14.47. Septerna, Inc. has a 1-year low of $4.17 and a 1-year high of $28.99.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in SEPN. RA Capital Management L.P. acquired a new position in shares of Septerna during the 4th quarter worth approximately $160,205,000. TRV GP V LLC acquired a new position in shares of Septerna during the 4th quarter worth approximately $142,337,000. TRV GP VI LLC acquired a new position in shares of Septerna during the 4th quarter worth approximately $72,191,000. Samsara BioCapital LLC purchased a new stake in shares of Septerna during the fourth quarter worth approximately $63,399,000. Finally, Driehaus Capital Management LLC purchased a new stake in shares of Septerna during the fourth quarter worth approximately $59,301,000.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Wells Fargo & Company downgraded Septerna from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $43.00 to $14.00 in a report on Tuesday, February 18th. JPMorgan Chase & Co. assumed coverage on Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $50.00 price target on shares of Septerna in a report on Tuesday, February 11th. Finally, TD Cowen assumed coverage on Septerna in a report on Tuesday, November 19th. They issued a “buy” rating for the company.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.